Abstract
Abstract. Recent changes in the classification of female sexual dysfunction in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the US Food and Drug Administration’s (FDA) approval of the first drug to treat low sexual desire in women (flibanserin) have highlighted the intense focus on sexual desire problems in women. We first discuss the rationale for the DSM changes and outline the DSM-5 criteria for Female Sexual Interest/Arousal Disorder. We provide an overview of some of the key events leading up to the approval of flibanserin for the treatment of hypoactive sexual desire disorder in women, including the role of the “Even the Score” advocacy campaign, that accused the FDA of gender bias in not giving women with sexual desire problems access to treatment options. Incorporating narratives from testimonials of female patients attending the 2014 FDA Patient-Focused Drug Development Public Meeting, we examine some of the prevalent beliefs around sexual “normalcy” and the immutability of sexual desire. We critique how the media and pharmaceutical companies depict sexual norms and female sexual desire and how pharmaceutical trials often narrowly define and assess sexual desire and “sex.” We end with some recommendations for how researchers, clinicians, and journalists can better acknowledge that sex and desire have multiple meanings and interpretations with a view to women being offered a truly informed choice when seeking help for sexual problems.
References
1952). Diagnostic and statistical manual of mental disorders (1st. ed.). Washington, DC: Author.
. (1968). Diagnostic and statistical manual of mental disorders (2nd. ed.). Washington, DC: Author.
. (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author.
. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.
. (2013). Diagnostic and statistical manual of mental disorders (5th. ed.). Arlington, VA: Author.
. (2010). The history of “female sexual dysfunction” as a mental disorder in the 20th Century. Current Opinion in Psychiatry, 23, 536–541. doi: 10.1097/YCO.0b013e32833db7a1
(2012). Contested psychiatric ontology and feminist critique: “Female Sexual Dysfunction” and the Diagnostic and Statistical Manual. History of the Human Sciences, 25, 3–24. doi: 10.1177/0952695112456949
(2015). Sense about sex: Media, sex advice, education and learning. Sex Education, 15, 528–539. doi: 10.1080/14681811.2015.1057635
(2002). The medicalization of female sexual dysfunction: The need for caution. Archives of Sexual Behavior, 31, 451–455. doi: 10.1023/A:1019800426980
(2001). Conceptualizing women’s sexual problems. Journal of Sex & Marital Therapy, 27, 95–103. doi: 10.1080/00926230152051716
(2000). The female sexual response: A different model. Journal of Sex & Marital Therapy, 26, 51–64. doi: 10.1080/009262300278641
(2000). Report of the international consensus development conference on female sexual dysfunction: Definitions and classifications. Journal of Urology, 163, 888–893. doi: 10.1016/S0022-5347(05)67828-7
(2015). Flibanserin for low sexual desire in women: A molecule from bench to bed? EBioMedicine, 2, 772–773. doi: 10.1016/j.ebiom.2015.08.009
(2003). Definitions of women’s sexual dysfunction reconsidered: Advocating expansion and revision. Journal of Psychosomatic Obstetrics and Gynaecology, 24, 221–229. doi: 10.3109/01674820309074686
(2002). Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. Journal of Women’s Health & Gender-Based Medicine, 11, 367–377. doi: 10.1089/152460902317586001
(1994).
(Gender, science, and sexual dysfunction . In T. R. SarbinJ. I. KituseEds., Constructing the social (pp. 101–118). London, UK: Sage.2010). The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior, 39, 221–239. doi: 10.1007/s10508-009-9543-1
(2016). Challenges in designing psychological treatment studies for sexual dysfunction. Journal of Sex and Marital Therapy, . doi: 10.1080/0092623X.2016.1212294
(2015). Women’s endorsement of different models of sexual functioning supports polythetic criteria of Female Sexual Interest/Arousal Disorder in DSM-5. Journal of Sexual Medicine, 12, 1978–1981. doi: 10.1111/jsm.12965
(2015). Big pharma, women, and the labour of love. Toronto, Ontario: University of Toronto Press.
(2001). The ambiguity of “having sex”: The subjective experience of virginity loss in the United States. Journal of Sex Research, 38, 127–139.
(2017). Controversies in women’s sexual arousal and desire. European Psychologist, 22. doi: 10.1027/1016-9040/a000275
(2016). Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Women’s Health, 12, 325–327. doi: 10.2217/whe-2016-0018
(2016). Conceptualization of the sexual response models in men: Are there differences between sexually functional and dysfunctional men? Journal of Sexual Medicine, 13, 453–463. doi: 10.1016/j.jsxm.2015.12.032
(2011). Should sexual desire and arousal disorders in women be merged? [Letter to the Editor]. Archives of Sexual Behavior, 2, 217–219. doi: 10.1007/s10508-010-9677-1
(2016). Future targets for female sexual dysfunction. Journal of Sexual Medicine, 13, 1147–1165. doi: 10.1016/j.jsxm.2016.05.016
(2002). What’s in a disorder: A cultural analysis of medical and pharmaceutical constructions of male and female sexual dysfunction. Women and Therapy, 24, 179–193. doi: 10.1300/J015v24n01_20
(2015). Orgasmic bodies. Basingstoke, UK: Palgrave MacMillan.
(2015). Efficacy and safety of flibanserin in women with Hypoactive Sexual Desire Disorder: A systematic review and meta-analysis. Journal of Sexual Medicine, 12, 2095–2104. doi: 10.1111/jsm.13037
(2015). Evaluation of flibanserin: Science and advocacy at the FDA. Journal of the American Medical Association, 314, 869–870. doi: 10.1001/jama.2015.8405
(2009). Conceptualizing women’s sexual function: Linear vs. circular models of sexual response. Journal of Sexual Medicine, 6, 2761–2771. doi: 10.1111/j.1743-6109.2009.01425.x
(2015). Endorsement of models describing sexual response of men and women with a sexual partner: An online survey in a population sample of Danish adults ages 20–65 years. Journal of Sexual Medicine, 12, 116–128. doi: 10.1111/jsm.12720
(2011). Continued efficacy and safety of libanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): Results from a randomized withdrawal trial. Journal of Sexual Medicine, 8, 3160–3170. doi: 10.1111/j.1743-6109.2011.02458.x
(2009). My turn… finally. The Journal of Sexual Medicine, 6, 301–302. doi: 10.1111/j.1743-6109.2008.01147.x
(2010). The DSM diagnostic criteria for female sexual arousal disorder. Archives of Sexual Behavior, 39, 240–255. doi: 10.1007/s10508-009-9535-1
(2016). Reconceptualising women’s sexual desire and arousal in DSM-5. Psychology & Sexuality, 7, 34–47. doi: 10.1080/19419899.2015.1024469
(2014). A response to Balon and Clayton (2013): Female Sexual Interest/Arousal Disorder: A diagnosis more on firm ground than thin air. Archives of Sexual Behavior, 43, 1231–1234. doi: 10.1007/s10508-013-0248-0
(2003).
(Eyes tightly shut, lying rigidly still and thinking of England? British women and sex from Marie Stopes to Hite . In M. MartinC. NelsonEds., Sexual Pedagogies: Teaching Sex in America, Britain, and Australia, 1879–2000 (pp. 53–71). Basingstoke, UK: Palgrave MacMillan.2004). Pfizer gives up testing Viagra in women. New York Times. February 28, 2004. http://www.nytimes.com/2004/02/28/business/pfizer-gives-up-testing-viagra-on-women.html?_r=0
(2008). What is the “true” prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? Journal of Sexual Medicine, 5, 777–787. doi: 10.1111/j.1743-6109.2007.00768.x
(2013). DSM-5 changes in diagnostic criteria of sexual dysfunctions. Reproductive System & Sexual Disorders, 2, 122. doi: 10.4172/2161-038X.1000122
(2016). Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. JAMA Internal Medicine, 176, 453–462. doi: 10.1001.jamainternmed.2015.8565
(2010). Framing disease: The example of female hypoactive sexual desire disorder. Social Science and Medicine, 70, 1084–1090. doi: 10.4172/2161-038X.1000122
(1974). The new sex therapy. New York, NY: Brunner/Mazel.
(E. KaschakL. Tiefer (2001). A new view of women’s sexual problems. New York, NY: Haworth Press.
2013). Efficacy of flibanserin in women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA trial. Journal of Sexual Medicine, 10, 1807–1815. doi: 10.1111/jsm.12189
(2008). What makes women experience desire? Feminism & Psychology, 18, 505–514. doi: 10.1177/0959353508095533
(2007).
(How do men and women feel? Determinants of subjective experience of sexual arousal . In E. JanssenEd., The psychophysiology of sex (pp. 278–290). Bloomington, IN: Indiana University Press.1999). Sexual dysfunctions in the United States: Prevalence and predictors. Journal of the American Medical Association, 281, 537–544. doi: 10.1001/jama.281.6.537
(T. LueR. BassonR. RosenF. GiulanoS. KhouryF. Montorsi (2004). Sexual medicine: Sexual dysfunctions in men and women. Paris, UK: Health Publications.
1966). Human sexual response. Boston, MD: Little, Brown.
(2004). Pfizer will not apply for a license for sildenafil for women. British Medical Journal, 328, 542. doi: 10.1136/bmj.328.7439.542
(2010). Elucidating women’s (hetero)sexual desire: Definitional challenges and content expansion. Journal of Sex Research, 47, 104–122. doi: 10.1080/00224490903402546
(2003). Sexual function problems and help seeking behaviour in Britain: National probability sample survey. British Medical Journal, 327, 426–427. doi: 110.1136/bmj.327.7412.426
(2008). Two challenges for the classification of sexual dysfunction. Journal of Sexual Medicine, 5, 1552–1558. doi: 10.1111/j.1743-6109.2008.00846.x
(2016). Estimating the prevalence of sexual function problems: The impact of morbidity criteria. Journal of Sex Research, 53, 955–967. doi: 10.1080/00224499.2015.1089214
(2013). Sexual function in Britain: Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). The Lancet, 382, 1817–1829. doi: 10.1016/ S0140-6736(13)62366-1
(2003). The making of a disease: Female sexual dysfunction. British Medical Journal, 326, 45–47. doi: 10.1136/bmj.326.7379.45
(2005). The marketing of a disease: Female sexual dysfunction. British Medical Journal, 330, 192–194. doi: 10.1136/bmj.330.7484.192
(2010). Sex, lies and pharmaceuticals: how drug companies plan to profit from female sexual dysfunction. Vancouver: Greystone.
(2010). Management of hypoactive sexual desire disorder in women: Current and emerging therapies. International Journal of Women’s Health, 2, 167–175. doi: 10.2147/IJWH.S7578
(2003). Problems with sexual function in people attending London general practitioners: Cross sectional study. British Medicine Journal, 327, 423–426. doi: 10.1136/bmj.327.7412.423
(2004). On categorization and quantification of women’s sexual dysfunctions: An epidemiological approach. International Journal of Impotence Research, 16, 261–269. doi: 10.1038/sj.ijir.3901151
(2001). Which behaviors constitute “having sex” among university students in the UK? Archives of Sexual Behavior, 30, 169–176. doi: 10.1023/A:1002777201416
(2007). Women’s endorsement of models of female sexual response: The nurses’ sexuality study. Journal of Sexual Medicine, 4, 708–719. doi: 10.1111/j.1743-6109.2007.00496.x
(2016). Sex, drugs, and advisory committees: An analysis of pharmaceutical industry manipulation of FDA vulnerability to sociopolitical influences on matters of women’s health. Columbia Human Rights Law Review, 48, 2016–2017.
(2010). Misclassification bias: Diversity in conceptualisations about having “had” sex. Sexual Health, 7, 31–34. doi: 10.1071/SH09068
(1999). Would you say you had sex if…? Journal of the American Medical Association, 281, 275–277. doi: 10.1001/jama.281.3.275
(2008). Sexual problems and distress in United States women: Prevalence and correlates. Obstetrics & Gynecology, 112, 970–978. doi: 10.1001/jama.281.3.275
(2014). Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause, 21, 633–640. doi: 10.1097/GME.0000000000000134
(2009). Commentary: Approved hormonal treatments for HSDD: An unmet medical need. The Journal of Sexual Medicine, 6, 1846–1849. doi: 10.1111/j.1743-6109.2009.01294.x
(2016). Solving desire. The New Inquiry, March 9, 2016.
(1991). Historical, scientific, clinical, and feminist criticisms of “the human sexual response cycle” model. Annual Review of Sex Research, 2, 1–23.
(2001).
(Arriving at a “New View” of women’s sexual problems: Background, theory, and activism . In E. KaschakL. TieferEds., A new view of women’s sexual problems (pp. 63–98). New York, NY: Haworth Press.2006). Female sexual dysfunction: A case study of disease mongering and activist resistance. PLoS Medicine, 3, 3178. doi: 10.1111/j.1743-6109.2009.01294.x
(2015). Missed opportunities in the Patient-Focused Drug Development Public Meeting and Scientific Workshop on Female Sexual Dysfunction held at the FDA, October 2014. Journal of Sex Research, 52, 601–603. doi: 10.1080/00224499.2014.1003362
(2015). Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin 1A receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study. European Journal of Pharmacology, 753, 246–251. doi: 10.1016/j.ejphar.2014.10.061
(2012). Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder. Clinical Investigation, 2, 423–432. doi: 10.4155/cli.12.18
(2008). Female sexual dysfunction, sexual distress, and compatibility with partner. Journal of Sexual Medicine, 5, 2587–2599. doi: 10.1111/j.1743-6109.2008.00984.x
(2016). US Food and Drug Administration approval of flibanserin: Even the Score does not add up. JAMA Internal Medicine, 176, 439–442. doi: 10.1001/jamainternmed.2016.0073
(2007). Negotiating sexual agency: Postmenopausal women’s meaning and experience of sexual desire. Qualitative Health Research, 17, 189–200. doi: 10.1177/1049732306297415
(